BCR‐ABL1 molecular remission after 90Y‐epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B‐ALL: proof of principle. (12th September 2013)

• Record Type: Journal Article
• Authors: Chevallier, Patrice; Bodet‐Milin, Caroline; Robillard, Nelly; Eugene, Thomas; Menard, Audrey; Le, Claire; Guillaume, Thierry; Delaunay, Jacques; Escoffre‐Barbe, Martine; Wegener, William A.; Goldenberg, David M.; Kraeber‐Bodéré, Francoise
• Is Part Of: European journal of haematology. Volume 91:Number 6(2013:Dec.)
• Page Start: 552
• Page End: 556
• Publication Date: 2013-09-12
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12183
• Languages: English
• ISSNs: 0902-4441

Abstract

<abstract abstract-type="main" id="ejh12183-abs-0001"> <title>Abstract</title> <p>Although targeted therapies are used increasingly in hematologic malignancies, we are unaware of any prior studies of radioimmunotherapy (RAIT) in B‐acute lymphoblastic leukemia (ALL), even though this radiosensitive tumor expresses CD22, potentially a good target for this approach. Here, we report a patient with Philadelphia chromosome‐positive B‐ALL in third relapse who received RAIT with ⁹⁰yttrium (⁹⁰Y)‐labeled anti‐CD22 epratuzumab tetraxetan. Seven weeks after initiating therapy, the patient achieved a BCR‐ABL1 molecular remission documented by RT‐qPCR, which is now continuing at 6 months while awaiting an allogeneic hematopoietic stem cell transplant. ⁹⁰Y‐Epratuzumab tetraxetan may be a promising therapeutic option for CD22⁺ B‐ALL patients.</p> </abstract>